The Last Breath: Historical Controversies Surrounding Determination of Cardiopulmonary Death.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
02 2022
Historique:
received: 17 06 2021
revised: 19 07 2021
accepted: 04 08 2021
pubmed: 18 8 2021
medline: 11 3 2022
entrez: 17 8 2021
Statut: ppublish

Résumé

Cardiopulmonary determination of death is a mainstay of the practice of internal medicine and pulmonary physicians. Despite this, there is considerable variability in death examinations. This article tracks the evolution of the tripartite death examination, initially developed in the middle of the 19th century to protect against premature burial. Although the societal context for controversies about death determination has shifted to discussions about end-of-life care in ICUs and organ transplantation, the cardiopulmonary death examination has largely remained unchanged from its original formulation. The recognition of coma dépassé and brain death has further pushed the focus of the death examination onto the neurological system. Despite advancing diagnostics and legislative attempts to standardize the definition of death, cardiopulmonary death determination largely remains an ad hoc process.

Identifiants

pubmed: 34400157
pii: S0012-3692(21)03631-X
doi: 10.1016/j.chest.2021.08.006
pii:
doi:

Types de publication

Historical Article Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

514-518

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Chest Physicians. All rights reserved.

Auteurs

Adam Rodman (A)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: arodman@bidmc.harvard.edu.

Anthony C Breu (AC)

Harvard Medical School, Boston, MA; Department of Medicine, Veteran Affairs Boston Healthcare System, West Roxbury, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH